Personalized cancer vaccination targets specific cancer mutations of the individual patient's tumor, also referred to as neoantigens. Such “bespoke” vaccines are now being tested in multiple cancers and in combination with checkpoint inhibitors. This session will discuss our computational methods for antigenic epitope prediction, antigen selection (personalized and shared neoantigens derived from frame-shift mutations), validation in vitro and in vivo and future directions for the field.

Citation Format: Nina Bhardwaj. Personalized cancer vaccines: Antigen selection and translation into the clinic [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr SY22-02.